Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06910709 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT06910709 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 48 participants.
The verdict
NCT06910709, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The main objective of the study is to assess the safety and tolerability of AMG 378 as single or multiple doses in healthy participants.
Interventions
- DRUG Placebo
- DRUG AMG 378
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-04-08 |
| Est. Completion | 2025-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06910709
The ClinicalTrials.gov registry entry for NCT06910709 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06910709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06910709 about?
NCT06910709 is a clinical study titled "Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants". The main objective of the study is to assess the safety and tolerability of AMG 378 as single or multiple doses in healthy participants.
What is the current status of trial NCT06910709?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-04-08. Estimated completion is 2025-12-02.
What interventions are being tested in trial NCT06910709?
The interventions under investigation include: Placebo (DRUG), AMG 378 (DRUG).
Who is sponsoring clinical trial NCT06910709?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.